TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02657434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
Study: NCT02557334

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose Strawberry Powder
Description: 40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Strawberry Powder
Description: 40 g freeze dried strawberry powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: 40 g color and taste matched placebo powder
Study: NCT01103726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 5 mg tablets, 15 mg single dose
Study: NCT04541732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic epidural block
Description: Patients who will be subjected to epidural block will be placed in the lateral position then, after sterilization of the skin, 21 G spinal needle will be inserted at T9-T11 intervertebral spaces. The epidural space will be located using the loss of resistance to air technique and a mixture of bupivacaine 0.25% + 50 μ fentanyl targeting T6 level will be injected following induction of general anaesthesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided bilateral quadratus lumborum block
Description: Patients who will be subjected to major abdominal surgeries will be placed in a supine position with a pillow under their side to obtain an appropriate view of quadratus lumborum muscle. After sterilization of the skin and ultrasound-guided identification of the quadratus lumborum muscle, 20 ml bupivacaine 0.25% + 25μ fentanyl will be injected on each side following induction of general anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction of general anaesthesia with propofol
Description: propofol: 1.5-2.5mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction of general anaesthesia with propofol
Description: propofol: 1.5-2.5mg/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Relaxant
Description: Atracurium : 0.5mg/Kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscle Relaxant
Description: Atracurium : 0.5mg/Kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of general anaesthesia
Description: Sevoflurane 0.7-1.5 MAC in 40% oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance of general anaesthesia
Description: Sevoflurane 0.7-1.5 MAC in 40% oxygen
Study: NCT02596828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
Study: NCT04399824

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Rate Brachytherapy
Description: Undergo HDR brachytherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT01103726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablets, single dose
Study: NCT02928718

Intervention type: PROCEDURE
Intervention: ERCP
Description: Two expert endoscopists will perform ERCP. Patients will be sedated with midazolam(2-5mg) and pethidine(25-50mg) with careful monitoring. Duodenoscope (TJF-240 or TJF-260; Olympus Corp., Tokyo, Japan) will be used. Cholangiography or pancreatography will be gathered after selective bile duct or pancreatic duct cannulation. Therapy such as endoscopic sphincterotomy, stent insertion, and etc., will be done.
Study: NCT03787095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered as an intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent for REGN2810, administered as an IV infusion
Study: NCT01700647

Intervention type: OTHER
Intervention: Breath test- sampling using ENose
Description: Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)

Intervention type: OTHER
Intervention: Breath test- sampling using ENose
Description: Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)

Intervention type: OTHER
Intervention: Breath test- sampling using ENose
Description: Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)

Intervention type: OTHER
Intervention: Laryngoscopy and bronchoscopy
Description: Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.

Intervention type: OTHER
Intervention: Laryngoscopy and bronchoscopy
Description: Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
Study: NCT04979715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physitherapy follow-up
Description: preoperative patient informaiton, information leaflet and Physiotherapy meeting will be held every 2 weeks for 3 months
Study: NCT00810316

Intervention type: DRUG
Group type: OTHER
Intervention: Alprazolam
Description: Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Alprazolam XR
Description: Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Clonazepam
Description: Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
Study: NCT02261350

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food fortification

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplements
Study: NCT01616108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
Study: NCT02312908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: For experimental treatment of RBD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill manufactured to mask clonazepam 0.5mg tablet
Study: NCT00858143

Intervention type: OTHER
Intervention: Non Interventional Observation
Description: Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
Study: NCT02208635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofortified Maize
Description: Participant in this arm were fed zinc biofortified maize (\~30 µg Zn/g).
Study: NCT04979715

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: no intervention; preoperative patient informaiton and information leaflet
Study: NCT02208635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortified Maize
Description: Participants in this arm were fed zinc-oxide fortified maize (total level of \~60 µg Zn/g).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Maize
Description: Participants in this arm were fed maize that was not fortified or biofortified (\~15 µg Zn/g maize).
Study: NCT04465552

Intervention type: OTHER
Intervention: Patients received standard of care treatment during hospitalization
Description: All patients admitted with covid-19 will be enrolled and followed for the duration of their hospitalization as well as during outpatient follow for up to 6 months, in those recovered, to assess clinical outcomes.
Study: NCT03917017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiomics and Watson artificial intelligence
Description: The artificial intelligence platform developed by IBM Watson can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.~The imaging histology can be used to conduct intraoperative navigation surgical resection and treatment monitoring, and established a prognosis model to predict the prognosis of patients by grading the results of postoperative follow-up and microvascular invasion of pathological liver cancer, so as to better achieve accurate diagnosis and treatment of the disease.
Study: NCT01700647

Intervention type: OTHER
Intervention: Laryngoscopy and bronchoscopy
Description: Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
Study: NCT01505972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six and three time schedule
Description: Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Four and two time schedule
Description: Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.
Study: NCT04570969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Insertion of bilateral catheters in the intersfacia space of erector spinae muscle
Study: NCT01886755

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ORS rehydration solution
Study: NCT01945073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Booklet (BK)
Description: The information booklet provides age appropriate explanation about SCD: inheritance patterns for the trait and common sickle cell disorders in the Jamaican population. It includes manifestations, complications and the necessary preventive and treatment advice. In addition, issues that are common to adolescents including sexual activity, contraceptive use, drug usage, career advice and developmental changes common to persons with the disease are also discussed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Booklet (BK)
Description: The information booklet provides age appropriate explanation about SCD: inheritance patterns for the trait and common sickle cell disorders in the Jamaican population. It includes manifestations, complications and the necessary preventive and treatment advice. In addition, issues that are common to adolescents including sexual activity, contraceptive use, drug usage, career advice and developmental changes common to persons with the disease are also discussed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formal Counselling (CB)
Description: The study coordinator will have a face to face counselling session, lasting about 30 minutes, with the adolescent and/or caregiver. This will include the use of the educational booklet as an education tool, as well as a thorough discussion on the disease process; its manifestations, effects, and specific concerns during the adolescent period; as well as clarification of common myths and misconceptions about the disease.
Study: NCT02912845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KamRAB - HRIG
Description: wound infiltration or IM injection
Study: NCT01305174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROTEGE GPS stent vs. VISI-PRO stent
Description: Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROTEGE GPS stent vs. VISI-PRO stent
Description: Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease
Study: NCT03681236

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitment maneuver
Description: Applying plateau pressure 30cmH₂O for 30 seconds to achieve alveolar inflation
Study: NCT01877746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of prednisone and azathioprine
Description: * Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of prednisone and azathioprine
Description: * Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention, only standard medical therapy
Study: NCT05040438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vax-NK/HCC
Description: autologous NK cells expanded ex vivo.
Study: NCT00185276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Description: Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Description: Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight
Study: NCT04801199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL-2009-0031 140 mg
Description: Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.
Study: NCT01886755

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03625492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Potentially Irritating Beverages
Description: This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adopting the USDA Healthy Eating Habits
Description: This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
Study: NCT03077243

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: 60- 70 Gy at 2 Gy/fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (or alternative)
Description: The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 -7 total doses.
Study: NCT03268902

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age
Study: NCT02364479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg Yisaipu
Description: Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg etanercept
Description: Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The injection method and frequency of placebo is the same as the other arms.
Study: NCT00730145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332334
Description: A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
Study: NCT00841646

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Monovalent inactivated influenza vaccine
Description: 2 doses of monovalent inactivated influenza vaccine with adjuvant
Study: NCT03608098

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short Pulse Duration
Description: The holmium laser device will be used on a short laser pulse duration setting (300 μs or 350 μs)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long Pulse Duration
Description: The holmuim laser device will be used on a long laser pulse duration setting (700 μs or 1500 μs)
Study: NCT01650844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School-Based Telemedicine Enhanced Asthma Management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Study: NCT03478020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125
Description: Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive
Description: COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)
Study: NCT04096963

Intervention type: DEVICE
Intervention: The WATCHMAN FLX Delivery System
Description: WATCHMAN FLX Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium
Study: NCT03868020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT01958333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise 1
Description: Low-intensity, low-volume cardiorespiratory exercise and strength training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise 2
Description: Medium-intensity, Medium-volume cardiorespiratory exercise and strength training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise 3
Description: High-intensity, High-volume cardiorespiratory exercise and strength training